Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Q. Guo



Author of

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-002 - PD-L1 Expression and FGFR1 Amplification in Chinese Stage III/IV Lung Squamous Carcinoma (ID 2478)

      09:30 - 09:30  |  Author(s): Q. Guo

      • Abstract
      • Slides

      Background:
      This study aims to explore status of PD-L1 expression and FGFR1 amplification in stage IIIB/IV SQC, further to analyze their correlation with clinicpothological characteristics, efficacy of gemcitabine based chemotherapy and prognosis of SQC patients.

      Methods:
      128 stage III/IV SQC patients were enrolled into this study from May 1[st] 2009 to May 31[st] 2014, all of which had complete clinical profile. 78 patients received gemcitabine-based chemotherapy. Immunohistochemistry (IHC) was used to detect PD-L1 expression, fluorescence in situ hybridization was applied to detect FGFR1 amplification. SPSS17.0 was used for statistical analysis.

      Results:
      80 (62.5%) SQC had IHC positive PD-L1 expression. PD-L1expression was significantly higher in male and smoker population than female and non-smoker, respectively. (gender: 65.5% VS. 22.2%, P=0.011; smoke histology 67.0% VS. 44.0%, P=0.039). PD-L1 expression had no significant relationship with objective response rate (ORR) and disease control rate(DCR) for gemcitabine-based chemotherapy(54.8% VS.59.7%, P =0.434 and P=0.840). However, the overall survival (OS) of PD-L1 negative SQC was significantly longer than PD-L1 positive group (29.8 vs. 20.1 months, P=0.001). 32 cases showed FGFR1 FISH positive (32/128, 25.0%), and stage III patients presented lower rate compared with stage IV SQC (17.1% vs. 36.5%, P=0.013). FGFR1 amplification had no relationship with ORR and DCR in patients treated with gemcitabine-base chemotherapy(32.3% VS.30.6%. P=0.663 and P=0.659). No correlation between PD-L1 expression and FGFR1 amplification was found (P=0.916).

      Conclusion:
      PD-L1 expression could act as a prognosis factor in Chinese stage III/IV SQC patients. PD-L1 expression and FGFR1 amplification might be irrelevant.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.